A positron emission tomography (PET) imaging agent developed by GE Healthcare, 18F flutemetamol, could help differentiate between Alzheimer's disease patients and healthy individuals. That is according to results of a phase II study presented at the Human Amyloid Imaging meeting held this month ...
Please Login to read the full article.
